DK0804228T3 - Lægemiddel indeholdende aktiveringspeptidet for protein C - Google Patents

Lægemiddel indeholdende aktiveringspeptidet for protein C

Info

Publication number
DK0804228T3
DK0804228T3 DK96901265T DK96901265T DK0804228T3 DK 0804228 T3 DK0804228 T3 DK 0804228T3 DK 96901265 T DK96901265 T DK 96901265T DK 96901265 T DK96901265 T DK 96901265T DK 0804228 T3 DK0804228 T3 DK 0804228T3
Authority
DK
Denmark
Prior art keywords
protein
activation peptide
drug containing
pharmaceutical preparation
inflammations
Prior art date
Application number
DK96901265T
Other languages
Danish (da)
English (en)
Inventor
Johann Eibl
Ludwig Pichler
Hans-Peter Schwarz
Peter Turecek
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of DK0804228T3 publication Critical patent/DK0804228T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK96901265T 1995-01-20 1996-01-12 Lægemiddel indeholdende aktiveringspeptidet for protein C DK0804228T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/375,777 US5571786A (en) 1990-08-16 1995-01-20 Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
PCT/EP1996/000126 WO1996022108A1 (en) 1995-01-20 1996-01-12 The use of activated protein c for preparing a pharmaceutical preparation

Publications (1)

Publication Number Publication Date
DK0804228T3 true DK0804228T3 (da) 2002-09-23

Family

ID=23482293

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96901265T DK0804228T3 (da) 1995-01-20 1996-01-12 Lægemiddel indeholdende aktiveringspeptidet for protein C

Country Status (9)

Country Link
US (1) US5571786A (de)
EP (1) EP0804228B1 (de)
JP (1) JP3330953B2 (de)
AT (2) AT409822B (de)
CA (1) CA2209931A1 (de)
DE (1) DE69621591T2 (de)
DK (1) DK0804228T3 (de)
ES (1) ES2177755T3 (de)
WO (1) WO1996022108A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT975775E (pt) * 1997-04-23 2004-07-30 Vlaams Interuniv Inst Biotech Sistema regulador para a expressao induzivel de genes com promotores lambdoides
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
EP1353702A2 (de) * 2000-05-22 2003-10-22 The Johns Hopkins University Genmanipulation der gefässtransplantat zur resistenz gegen erkrankungen
JP4351041B2 (ja) * 2001-06-13 2009-10-28 ザ・ユニバーシティ・オブ・シドニー 傷治癒のための処置および組成物
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
BR0315942A (pt) 2002-11-27 2005-10-04 Dmi Biosciences Inc Tratamento de doenças e condições mediadas pelo aumento de fosforilação
PL2857037T3 (pl) 2012-05-31 2019-12-31 Kinki University Środek do leczenia profilaktycznego i/lub terapeutycznego obwodowego bólu neuropatycznego wywoływanego przez środek przeciwnowotworowy
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
JP2017513944A (ja) 2014-04-16 2017-06-01 ジージー バイオテック エルエルシー 異常な皮膚瘢痕化の治療
CA2946032C (en) 2014-04-16 2022-06-14 Zz Biotech Llc Use of apc analogue for wound healing
WO2020067389A1 (ja) 2018-09-28 2020-04-02 旭化成ファーマ株式会社 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US4908314A (en) * 1987-07-02 1990-03-13 American National Red Cross Protein C activator
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JP2774156B2 (ja) * 1989-09-05 1998-07-09 帝人株式会社 ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation

Also Published As

Publication number Publication date
WO1996022108A1 (en) 1996-07-25
EP0804228B1 (de) 2002-06-05
ES2177755T3 (es) 2002-12-16
EP0804228A1 (de) 1997-11-05
CA2209931A1 (en) 1996-07-25
JP3330953B2 (ja) 2002-10-07
ATE218368T1 (de) 2002-06-15
JPH11502508A (ja) 1999-03-02
DE69621591D1 (de) 2002-07-11
US5571786A (en) 1996-11-05
DE69621591T2 (de) 2003-01-16
AT409822B (de) 2002-11-25
ATA901196A (de) 2002-04-15

Similar Documents

Publication Publication Date Title
AU649421B2 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
DK0804228T3 (da) Lægemiddel indeholdende aktiveringspeptidet for protein C
IL116856A0 (en) Stable-lipid- comprising drug delivery complexes and methods for their production
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
DK0493480T3 (da) Dehydrodidemnin B
CA2119149A1 (fr) Medicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bacteries filamenteuses non photosynthetiques et non fructifiantes, et sa preparation
DE68910892D1 (de) Arzneimittel zur Verhütung von sexuell übertragbaren Krankheiten.
SE8804570D0 (sv) New ciclosporin crystal form process for its produktion pharmaceutical compositions containing it and its use
MA24339A1 (fr) Procede de preparation de medicaments destines au traitement d'infections bacteriennes en pediaterie
DK160429C (da) N-heterocyclisk glycosid med antitumorvirkning, fremstilling deraf samt farmaceutisk praeparat indeholdende glycosidet
ZA963826B (en) A method of treatment of mania and bipolar disorder
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
ATE259654T1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
CA2041380A1 (en) Use of protein c or activated protein c for preparing a pharmaceutical preparation
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
WO1997017072A3 (de) Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
FR2632525B1 (fr) Application therapeutique de la myeloperoxydase humaine
BR9609801A (pt) Petídos cíclicos análogos de somatostina com atividade inibitória do desenvolvimento de hormónio
EP0723454A4 (de) Für die immun- und cns-therapir nutzbare, neuartige tripeptide
FI872459A7 (fi) Farmaseuttinen valmiste bakteeri-infektioiden hoitoon.